Steady State Health | 5 Min Read
Meet “S,” a 51-year-old executive with a demanding career, a busy family life, and a long history of being “disciplined” about her health.
She exercised regularly.
She ate thoughtfully.
She tracked protein.
She slept as best she could.
And yet, over the past three years, her weight crept up — especially around her midsection — despite doing everything she had always been told was “right.”
When her clinician suggested a GLP-1 medication, Sarah felt hopeful for the first time in years.
At first, it worked.
Then… it didn’t.
After an initial drop of 10 pounds, the scale stalled. Hunger returned. Fatigue worsened. Her confidence plummeted.
She began to wonder: Why isn’t this working for me?
At Steady State Health, we knew the answer likely wasn’t “try harder.”
It looked deeper.
Step 1: Listening First — Understanding the Full Picture
Before adjusting medications or blaming “noncompliance,” we started where we always do: listening.
Sarah shared:
- Gradual weight gain despite consistent habits
- Increasing belly fat
- Poor sleep with frequent nighttime awakenings
- Low energy and afternoon crashes
- Mood changes and irritability
- Reduced stress tolerance
- Brain fog and slower recall
- A sense that her body was no longer responding the way it used to
She had been told:
“GLP-1s don’t work for everyone.”
But that explanation ignores an essential truth: midlife women are not metabolically neutral.
Weight regulation during perimenopause and menopause is influenced by:
- Estrogen decline
- Progesterone loss
- Insulin sensitivity changes
- Sleep disruption
- Increased cortisol
- Shifts in fat storage patterns
No medication works in isolation from those systems.
Step 2: Reframing the Question
Instead of asking:
“Why isn’t the GLP-1 working?”
We asked:
“What’s happening hormonally that may be blocking its effectiveness?”
GLP-1 medications help regulate appetite and blood sugar — but they don’t replace estrogen, fix sleep deprivation, or correct metabolic slowdown caused by hormonal shifts.
That distinction matters.
Step 3: Comprehensive Lab Evaluation — Removing the Guesswork
To understand Sarah’s stalled response, we ordered targeted labs.
Hormones
- Estradiol
- Progesterone
- FSH / LH
- Testosterone
- SHBG
- DHEA-S
Metabolic Markers
- Fasting insulin
- Hemoglobin A1c
- Lipid panel
Thyroid
- TSH
- Free T3
- Free T4
Nutrients & Inflammation
- Ferritin
- Vitamin D
- B12 and folate
- Magnesium
- hs-CRP
Her results showed:
- Low, fluctuating estrogen
- Minimal progesterone production
- Early insulin resistance
- Mild thyroid inefficiency
- Low ferritin contributing to fatigue
None of these were severe on their own — but together, they explained exactly why her body wasn’t responding optimally.
Step 4: Addressing Hormones First — Not Ignoring Them
We discussed evidence-based hormone replacement therapy, emphasizing safety, personalization, and shared decision-making.
Progesterone
- Supported deeper, more restorative sleep
- Reduced nighttime awakenings
- Improved stress resilience
Estrogen Therapy
- Improved insulin sensitivity
- Reduced visceral fat signaling
- Supported metabolic flexibility
- Improved mood and cognitive clarity
This step wasn’t about weight loss alone — it was about restoring physiologic balance.
Step 5: Sleep Optimization — The Metabolic Accelerator
Poor sleep directly interferes with:
- Appetite regulation
- Fat oxidation
- Insulin sensitivity
- GLP-1 responsiveness
We addressed:
- Hormone-supported sleep
- Consistent sleep-wake timing
- Evening routines that lowered cortisol
- Screening for sleep-disordered breathing when indicated
Within weeks, Sarah reported:
- Falling asleep faster
- Fewer awakenings
- More energy in the morning
Sleep was no longer sabotaging her metabolism.
Step 6: Nutrition & Movement — Supporting, Not Punishing the Body
We refined her approach:
- Adequate protein without restriction
- 30–40 g fiber daily to support gut health and estrogen metabolism
- Blood-sugar-stable meals
- Anti-inflammatory food patterns
Movement focused on:
- Strength training 2–3x/week
- Low-impact cardio
- Daily NEAT (non-exercise activity)
- Avoiding overtraining during symptomatic days
This created a hormone-friendly metabolic environment.
Step 7: Reintroducing GLP-1 Therapy — With the Right Foundation
Once hormones, sleep, and metabolic stress were addressed, we resumed GLP-1 therapy — without increasing her dose.
This time, the response was different.
GLP-1 supported:
- Predictable appetite control
- Improved insulin sensitivity
- Reduced inflammation
- Less emotional eating
- Steadier energy
The medication could finally do what it was designed to do — because the body was ready.
The Result
Over the following months, Sarah experienced:
- Consistent, sustainable weight loss
- Reduction in central (belly) fat
- Improved energy and mood
- Better sleep quality
- Reduced cravings
- Renewed trust in her body
She told us:
“This is the first time I don’t feel like I’m fighting myself.”
Why This Matters
GLP-1 medications are powerful tools — but they are not standalone solutions, especially for women in midlife.
When estrogen, progesterone, sleep, and metabolic health are ignored:
- Weight loss stalls
- Side effects increase
- Women blame themselves
When we address the whole system, results change.
If you’ve tried GLP-1 therapy and felt disappointed — or if weight loss feels harder than it ever used to — you’re not broken, and you’re not failing.
You deserve care that looks at:
- Hormones
- Metabolism
- Sleep
- Nutrition
- The full picture
At Steady State Health, we specialize in whole-person, evidence-based care for midlife women who are tired of being dismissed.
GET IN TOUCH
References (APA Format)
Stuenkel, C. A., et al. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.
https://doi.org/10.1097/GME.0000000000002028
Lovejoy, J. C. (2020). Weight gain in women at midlife: The influence of menopause. Obesity Management, 16(1), 7–10.
Ji, Y., et al. (2023). GLP-1 receptor agonists and their influence on mood, appetite, and cognition: Emerging evidence. Neuropsychopharmacology Reports, 43(2), 123–135.
